TFS Financial (NASDAQ:TFSL) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. This is a 33.33 percent increase over earnings of $0.06 per share from the same period last year.
AstraZeneca Announced Saphnelo Approved in Japan for Systemic Lupus Erythematosus
AstraZeneca's Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE), a serious autoimmune disease, who show insufficient response to currently available treatment.
